A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or A
Clinical Trial Grant
Administered By
Pediatrics, Rheumatology
Awarded By
Cabaletta Bio, Inc.
Start Date
June 23, 2025
End Date
July 1, 2028
Administered By
Pediatrics, Rheumatology
Awarded By
Cabaletta Bio, Inc.
Start Date
June 23, 2025
End Date
July 1, 2028